Page last updated: 2024-12-08

o-demethylmetoprolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

O-demethylmetoprolol: pharmacologically active urinary metoprolol metabolite 5 to 10X less potent than metoprolol; structure in first source; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID162181
CHEMBL ID3544687
SCHEMBL ID3462992
MeSH IDM0094096

Synonyms (33)

Synonym
62572-94-5
benzeneethanol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-
sl 80-0088
o-demethylmetoprolol
h105-22
h 105/22
1-[4-(2-hydroxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
FT-0666173
unii-9977tav7fg
9977tav7fg ,
o-desmethyl metoprolol
(+/-)-o-demethylmetoprolol
SCHEMBL3462992
o-desmethylmetoprolol
metoprolol succinate impurity h [ep impurity]
betaxolol hydrochloride impurity b [ep impurity]
(+/-)-4-(2-hydroxy-3-(isopropylamino)propoxy)phenylethyl alcohol
metoprolol tartrate impurity h [ep impurity]
CUKXSBOAIJILRY-UHFFFAOYSA-N
1-[4-[(2-hydroxyethyl)]phenoxy]-3[(1-methylethyl)amino]-2-propanol
CHEMBL3544687
o-demethylmetoprolol, analytical standard
AKOS030255796
C90510
(2rs)-1-[4-(2-hydroxyethyl)phenoxy]-3-[(1-methylethyl)amino]propan-2-ol
mpl-dm
metoprolol impurity 08;o-desmethyl metoprolol
1-(4-(2-hydroxyethyl)phenoxy)-3-(isopropylamino)propan-2-ol
1-[4-(2-hydroxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol
DTXSID40978153
Q27272183
4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-benzeneethanol;(+/-)-4-[2-hydroxy-3-(isopropylamino)propoxy]phenylethyl alcohol
ortho-desmethylmetoprolol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" 3 Areas under the plasma concentration curve for metoprolol after repeated administration are greater than would be predicted from single dose data, and possible explanations for this are discussed."( The effect of age on the pharmacokinetics of metoprolol and its metabolites.
Jack, DB; Kendall, MJ; Quarterman, CP, 1981
)
0.26

Dosage Studied

ExcerptRelevanceReference
" As a result, after oral dosing the peak plasma concentrations during pregnancy were only 12% to 55% those after delivery, and the plasma AUCs were reduced to the same extent."( Pregnancy-induced increase in metoprolol metabolism.
Högstedt, S; Lindberg, B; Peng, DR; Rane, A; Regårdh, CG, 1985
)
0.27
" Concentrations of the pharmacologically active metabolite, H119/66, remain unaltered during chronic dosing of metoprolol."( The effect of age on the pharmacokinetics of metoprolol and its metabolites.
Jack, DB; Kendall, MJ; Quarterman, CP, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Metoprolol Pathway, Pharmacokinetics44

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.54 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]